Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its partnership with clinical sites in Italy.
The Company has partnered with "Gruppo Italiano Mammella" (GIM), the largest academic cooperative breast cancer research group in Italy, including over 150 participating centers and approximately 500 investigators, with 28 clinical trials on-going today. GIM conducts independent research in innovative technologies and overall, more than 16,000 patients have been involved in approximately 30 studies conducted by the group so far.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.